$7.7 MILL GENZYME TRANSGENICS JV
Genzyme Transgenics, a majority- owned subsidiary of Genzyme Corp, has reported that the parties involved in its Japanese joint venture, SMI Genzyme Ltd, have committed up to a further $7.7 million in additional capital to fund development and marketing of transgenically-produced proteins.
SMI Genzyme has agreed to fund both a new three-year technology development and a two-year program at Genzyme Transgenics for preclinical development of recombinant human antithrombin III in the milk of transgenic goats. The company expects AT-III to be the first transgenically produced product to begin human clinical trials, targeted for late 1995. The product is currently available in a form derived from human plasma.
Genzyme Transgenics also announced five new commercial collaborations for recombinant therapeutic, diagnostic and processing proteins. These are:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze